FDA Lifts Clinical Hold on Phase II Trial of JCAR015 in ALL

July 12, 2016 10:14 PM

9 0

In a phase I study that included 51 adult patients with ALL,1 the CR rate with JCAR015 was 77% in those with morphologic disease (n = 31) and 90% in those with minimal disease (n = 20). At the time of the analysis, the median overall survival (OS) was not yet reached for those in the minimal disease arm. The median OS was 9 months for those with morphologic disease.

"We remain encourage by the ability of JCAR015 to treat ALL," said Hans Bishop, CEO at Juno Therapeutics. "The [ASCO] results show a marked improvement over traditional cytotoxic chemotherapy for adult ALL patients."

Also read: Jury In S.C. Police Shooting Trial Says It Is Struggling To Reach Verdict

Read more

To category page

Loading...